In GISTs, USP32 protects Ras-related protein Rab-35 (Rab35) from proteasomal degradation, leading to tumor resistance to Imatinib, a tyrosine kinase inhibitor that is wildly used to combat GISTs [11]. This evidence concerns the gene RAB35 and neoplasm.